octreotide in gastrointestinal malignancy
Last reviewed 01/2018
Octreotide therapy has been shown to prolong survival in patients with advanced, chemotherapy-resistant gastrointestinal cancers of the:
- stomach
- pancreas
- colon and rectum
Reference:
- Cascinu, S. et al. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Brit. J. Cancer 1995;71: 97-101.
- Rinke, A., H.H. Muller, C. Schade-Brittinger, K.J. Klose, P. Barth, M. Wied, et al., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol, 2009. 27(28): p. 4656-63.